Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain.
It operates through two segments, Sorrento Therapeutics and Scilex.
The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease.
The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia.
It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia.
It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma.
The company was founded in 2006 and is based in San Diego, California.
On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the Southern District of Texas.
The plan was later approved as C
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 23 | 0.00 Increased by +100.00% | -0.15 Increased by +100.00% |
| May 23, 23 | -0.26 Decreased by -116.67% | -0.16 Decreased by -62.50% |
| Mar 9, 23 | -0.23 Increased by +51.06% | -0.19 Decreased by -21.05% |
| Nov 8, 22 | -0.20 Increased by +50.00% | -0.25 Increased by +20.00% |
| Aug 15, 22 | -0.54 Increased by +5.26% | -0.25 Decreased by -116.00% |
| May 5, 22 | -0.12 Decreased by -1.30 K% | -0.17 Increased by +29.41% |
| Mar 11, 22 | -0.47 Decreased by -74.07% | -0.29 Decreased by -62.07% |
| Nov 5, 21 | -0.40 Decreased by -21.21% | -0.23 Decreased by -73.91% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 15.03 M Increased by +31.10% | -95.21 M Increased by +56.63% | Decreased by -633.69% Increased by +66.92% |
| Mar 31, 23 | 16.25 M Decreased by -11.61% | -139.62 M Decreased by -245.51% | Decreased by -859.12% Decreased by -290.88% |
| Dec 31, 22 | 15.59 M Increased by +19.26% | -208.69 M Decreased by -43.91% | Decreased by -1.34 K% Decreased by -20.67% |
| Sep 30, 22 | 17.40 M Increased by +44.25% | -90.69 M Increased by +24.30% | Decreased by -521.19% Increased by +47.53% |
| Jun 30, 22 | 11.46 M Decreased by -15.17% | -219.55 M Decreased by -31.77% | Decreased by -1.92 K% Decreased by -55.34% |
| Mar 31, 22 | 18.39 M Increased by +28.97% | -40.41 M Decreased by -1.71 K% | Decreased by -219.79% Decreased by -1.35 K% |
| Dec 31, 21 | 13.08 M Increased by +13.65% | -145.01 M Decreased by -102.81% | Decreased by -1.11 K% Decreased by -78.44% |
| Sep 30, 21 | 12.06 M Increased by +2.63% | -119.80 M Decreased by -42.58% | Decreased by -993.23% Decreased by -38.93% |